Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
Date:10/23/2008

elephone replay will be available through November 6, 2008.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non- nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to the expected timing and planned development activities for ANA598 and ANA773, including the trial design, occurrence, timing, and pace of future clinical trials, the timing for obtaining viral load data and expectations regarding such data, as well as the anticipated future clinical benefits of ANA598 and ANA773. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward- looking statements. For example, the results of preclinical studies and early clinical trials may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. In addition, Anadys' results may be affected by competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into collaborations around its product candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical t
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... NJ (PRWEB) May 21, 2015 Patent ... a method for diagnostic or therapeutic imaging within a ... apparatus uses an endoscope having a low cost, single-use ... USPTO filing date was October 18, 2013 and the ... The technology enables the physician to customize the lighting ...
(Date:5/21/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: RP) ... focused on the development of autologous cell therapies, ... International Society for Cellular Therapy (ISCT) on RepliCel,s ... in a Phase 1/2 clinical trial.  The presentation, ... 5:30 PM to 7:00 PM local time, will ...
(Date:5/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/x4b7kw/top_technologies ) ... in HW_Technical Insights" report to their offering. ... trends in the Health and Wellness sector and has ... an impact in the year 2015. The research service ... health and wellness technologies that are anticipated to have ...
(Date:5/20/2015)... global genotyping market is expected to grow at a ... to 2020 to reach $17.0billion in 2020. Genotyping tests ... process and to provide personalized therapy, factors that are ... key manufacturers to offer advanced and innovative products for ... market data tables & 37 figures spread through 200 ...
Breaking Biology Technology:IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Top Technologies in the Health and Wellness Industry 2015 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5
... DARA BioSciences(TM),(Nasdaq: DARA ) announced today the appointment ... Mr. Cochrane was appointed to fill a Board,vacancy and ... appointment was effective February 21, 2008., In making ... are pleased that Haywood has joined us as a ...
... PITTSBURGH, Feb. 27 Mylan Inc. (NYSE: ... Holdings, Ltd., a wholly,owned subsidiary of Forest Laboratories, ... 2006 agreement to commercialize, develop and distribute the,novel ... in,the United States for the treatment of hypertension. ...
... ZARS Pharma, Inc. announced,today that Rapydan(R) (70 ... received marketing authorization in Sweden, the United ... Republic, Greece, Ireland,Norway and Portugal following the ... Pharma has licensed the European sales and,marketing ...
Cached Biology Technology:DARA BioSciences, Inc. Announces Appointment of New Director to Board 2Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement 2Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement 3ZARS Pharma Announces Marketing Authorization of Rapydan(R) in Europe 2ZARS Pharma Announces Marketing Authorization of Rapydan(R) in Europe 3
(Date:5/11/2015)... SAN JOSE, Calif. , May 11, 2015 ... leading developer of human interface solutions, today announced ... Senior Vice President and Chief Financial Officer, reporting ... Mr. Ali replaces Synaptics, current Chief Financial Officer, ... in December 2014. Mr. Ali ...
(Date:5/11/2015)... May 11, 2015 Curemark LLC, a privately ... of a new Phase III double blind, randomized, placebo-controlled ... formulation, CM-AT, on all children ages 3-8 with Autism. ... Phase III double blinded clinical trial for CM-AT in ... of the digestive enzyme chymotrypsin. This new trial will ...
(Date:5/8/2015)... , May 8, 2015 Synaptics Inc. (NASDAQ: ... announced that members of the executive management team will present ... Annual Technology, Media and Telecom Conference Date: May 18, ... Boston, MA Cowen and ... Time: 2:45pm ET Location: The New York Palace Hotel, ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2
... University has completed the first comprehensive map of the ... of higher organisms operate, according to a report this ... is a breakthrough in understanding mechanisms of how proteins ... master regulator molecules called protein kinases. Although protein kinases ...
... volcanic rock in Mexico are either extremely old - more ... presence in the Western Hemisphere - or not footprints at ... Nature. , The study was conducted by geologists at the ... part of an investigative team of geologists and anthropologists from ...
... strand of molecules plays a role in how our arms ... light on perplexing bits of material once dismissed as genetic ... University. , The research, available today in the online edition ... called microRNAs act as protective mechanisms in healthy development not ...
Cached Biology News:Yale scientists decipher 'wiring pattern' of cell signaling networks 2Alleged 40,000-year-old human footprints in Mexico much, much older than thought 2Alleged 40,000-year-old human footprints in Mexico much, much older than thought 3Alleged 40,000-year-old human footprints in Mexico much, much older than thought 4MicroRNA may have fail-safe role in limb development 2